Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 301–400 of 1,000
Dong, W., Bai, J., Yuan, Q., Zhang, Y., Zhang, Y., Zhang, Z., Yang, M., Li, H., Zhao, Z., & Jiang, H. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105791 · Cited by 32
Long-Acting Human Growth Hormone Analogue by Noncovalent Albumin Binding
Ramírez-Andersen, H. S., Behrens, C., Buchardt, J., Fels, J. J., Folkesson, C. G., Chen, J., Nørskov‐Lauritsen, L., Nielsen, P. F., Reslow, M., Rischel, C., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00463 · Cited by 31
Self-citationGenetically Encoding a Lipidated Amino Acid for Extension of Protein Half‐Life in vivo
Fu, C., Chen, Q., Zheng, F. J., Yang, L., Li, H., Zhao, Q., Wang, X., Wang, L., & Wang, Q. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811837 · Cited by 30
Lear, S., Pflimlin, E., Zhou, Z., Huang, D., Weng, S., Nguyen-Tran, V. T. B., Joseph, S. B., Roller, S. G., Peterson, S., Li, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00740 · Cited by 31
Shi, A., Xie, P., Nielsen, L. L., Skjøth, T. V., He, X., & Haugaard, S. P. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01548-y · Cited by 32
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 42
“Semaglutide is a long-acting GLP-1RA with a half-life (t 1⁄2 ) of approximately 1 week.(19) Consequently, subcutaneous semaglutide is administered once weekly.”
BackgroundAntza, C., Nirantharakumar, K., Doundoulakis, I., Tahrani, A. A., & Toulis, K. A. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s166765 · Cited by 30
“The strong affinity for albumin also contributes to the long duration of action.(17,19) The spacer region (glutamic acid moiety) between the C-18 fatty di-acid sidechain and the peptide is considered to be important for potency, whereas the fatty acid is considered to be important for both potency and protraction.”
Key milestones in the diabetes research: A comprehensive update
Gupta, A. K., Behl, T., & Sachdeva, M. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100183 · Cited by 33
Future directions in obesity pharmacotherapy
Finer, N. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.024 · Cited by 32
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
“OW semaglutide is indicated in subjects with uncontrolled type 2 diabetes as a monotherapy when the use of metformin is contraindicated, or as an add-on therapy with other glucoselowering drugs, including insulin (18, 19); furthermore, based on the most recent guidelines, it can be considered for use as a first-line t…”
BackgroundIkushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
“Semaglutide’s structural modifications from native GLP-1 make it less susceptible to degradation by dipeptidyl peptidase 4 (DPP-4) and, in addition, increase its specific high-affinity binding to albumin [21].”
BackgroundInfluentialJordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“Semaglutide, dulaglutide, and tirzepatide utilize albumin binding and improved fatty acid attachment, which results in a longer half-life [44,205].”
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
“Semaglutide injection involves the addition of a fatty acid side chain at the 26th position of the natural GLP-1 peptide chain, which can inhibit the degradation by DPP-4, thereby extending the half-life of semaglutide injection to one week 81 .”
Lee, J. W., Park, J., Yu, G. W., You, J. W., Han, M. J., Kang, M. J., & Ho, M. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101350 · Cited by 32
“…(with two carboxylic acid groups) and liraglutide’s C12 linker (single carboxylic acid) alter drug–polymer interactions, leading to variable release kinetics; in some cases, only ~50% of the payload is released over extended periods, with the remainder trapped in the polymer matrix [114,115].”
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“The third strategy is to slow down absorption and to reduce renal elimination by fusion with larger carrier molecules such as albumin (albiglutide; Tomkin, 2009; Trujillo and Nuffer, 2014) or Fc fragments of immunoglobulin G (dulaglutide; Scheen, 2016) or by attachment of a fatty-acid side-chain that allows reversible…”
BackgroundTherapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
Kim, H. R., Taslakjian, B., Kim, S., Tirrell, M., & Guler, M. O. (2024) · ChemBioChem · doi:10.1002/cbic.202300831 · Cited by 30
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
“26,27 Purification was achieved using preparative high-performance liquid chromatography on C18 reverse-phase columns, with 0.1% TFA in water and 0.1% TFA in acetonitrile as eluents, followed by lyophilisation.”
InfluentialSelf-citationZheng, Y.-C., He, H., Wei, X., Ge, S., & Lü, Y. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03845 · Cited by 28
Long acting growth hormone (LAGH), an update
Grillo, M. S., Frank, J., & Saenger, P. H. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1254231 · Cited by 27
“Similar technologies to enhance the half-life of other peptide drugs, such as long-acting insulin detemir, glucagon-like peptide-1 molecules liraglutide (28, 29), and semaglutide (30).”
BackgroundRroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
Zhang, L., Navaratna, T. A., & Thurber, G. M. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00209 · Cited by 29
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Are peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02385-x · Cited by 26
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 30
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice
Sun, L., Shang, B., Lv, S., Liu, G., Wu, Q., & Geng, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1562896 · Cited by 41
Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges
Hijazi, Y. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00664-y · Cited by 27
Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
Li, C., Wan, L., Luo, J., Jiang, M., & Wang, K. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s283416 · Cited by 27
“In addition to these two drugs, some novel GLP-1 receptor agonists have been developed and used,(10) such as another short-acting drug lixisenatide,(11,12) and other long-acting drugs, such as albiglutide,(13,14) dulaglutide,(15,16) and semaglutide.(17) In addition, long-acting GLP-1Ras requires weekly subcutaneous ad…”
BackgroundThe industrial design, translation, and development strategies for long-acting peptide delivery
Yang, B., dos Santos, A. G., Puri, S., Bak, A., & Zhou, L. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2098276 · Cited by 28
“20 carbons) and the transitioning from monocarboxylic acids to dicarboxylic acids [24].”
BackgroundInfluentialGlucagon-like peptide 1 aggregates into low-molecular-weight oligomers off-pathway to fibrillation
Brichtová, E., Krupová, M., Bouř, P., Lindo, V., dos Santos, A. G., & Jackson, S. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.04.027 · Cited by 28
“GLP-1 is an important therapeutic peptide drug and its derivatives are widely used in the treatment of type 2 diabetes (3,4,53–57).”
BackgroundNature-inspired and medicinally relevant short peptides
Ciulla, M. G., Civera, M., Sattin, S., & Kumar, K. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00011 · Cited by 28
He, M. M., Zhu, S. X., Cannon, J. R., Christensen, J. K., Duggal, R., Gunduz, M., Hilgendorf, C., Hughes, A., Kekessie, I., Kullmann, M., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001437 · Cited by 27
“5) at the second position, an alanine residue, resulting in a circulating half-life of ~2 minutes in humans (Lau et al., 2015).”
BackgroundInfluentialZhao, Q., Dong, J., Liu, H., Chen, H., Yu, H., Ye, S., Yu, S., Yu, L., Qiu, L., Song, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.020 · Cited by 27
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“This limitation has led to the development of long-acting GLP-1Ras, such as semaglutide (Knudsen & Lau, 2019; Lau et al., 2015).”
Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus
Hasan, M. N., Hwang, Y. H., An, J. M., Shahriar, S. M. S., Cho, S., & Lee, Y.-K. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c09814 · Cited by 26
Novel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 27
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
“Semaglutide (NN9924/OG217SC; Novo Nordisk) is similar in structure to liraglutide and is resistant to degradation by DPP-4 because it is derivatized at lysine 26 [93].”
BackgroundA GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
Douros, J. D., Novikoff, A., DUBOIS, B. N., Rohlfs, R., Mokrosiński, J., Hogendorf, W. F. J., Augustin, R., Merkestein, M., Martini, L. B. E., Linderoth, L., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102124 · Cited by 26
“…notably semaglutide, the molecular engineering and in vitro pharmacology primarily focused on optimizing Gs α /cAMP signaling potency and prolonged half-life, with little consideration of β -arrestin recruitment, under the assumption that this would result in maximal efficacy in vivo [2,3].”
Self-citationThe Global Challenges of Type 2 Diabetes
Rob, A., Hoque, A., Miah, M. A., Khatoon, M. A. A., Khalil, R., Thomas, D., Ilyas, M., Mahmood, H., & Chowdhury, T. A. (2025) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v36i2.78406 · Cited by 35
“22 Their prolonged action is achieved through increased albumin affinity as well as stability against metabolic degradation .”
Kim, J., Kim, J., Choi, C., Bae, J., & Choi, H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01497-y · Cited by 26
“Semaglutide, a more recent GLP-1 analog (marketed as Ozempic for diabetes and Wegovy for obesity), further improves upon this design 151 .”
Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder
Kim, T. Y., Park, J., Shim, H. E., Choi, D. S., Lee, D., Song, J., & Kim, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.017 · Cited by 25
“whole peptide was chemically synthesized to incorporate non-natural amino acid at specific position for fatty acid conjugation [17,24].”
MethodChen, X., Fu, J., Zhou, F. L., Yang, Q., Wang, J., Feng, H., Jiang, W., Jin, L., Tang, X., Jiang, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00736 · Cited by 26
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
Himmerich, H., Bentley, J., & McElroy, S. L. (2024) · CNS Drugs · doi:10.1007/s40263-024-01111-1 · Cited by 31
“GLP-1 receptor agonists, such as liraglutide, semaglutide, and exenatide, were identified in diabetes research as weight loss drugs [68, 69].”
Recent Advances in Augmenting the Therapeutic Efficacy of Peptide–Drug Conjugates
Ma, J., Wang, X., Hu, Y., Ma, J., Ma, Y., Chen, H., & Han, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00007 · Cited by 27
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
“Such drugs are designed to stay in the blood for a very long time to ensure protection against hyperglycemia [206, 207].”
Adapting the Glaser Reaction for Bioconjugation: Robust Access to Structurally Simple, Rigid Linkers
Silvestri, A. P., Cistrone, P. A., & Dawson, P. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201705065 · Cited by 27
New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
“The efficacy and convenience of once-a-week GLP-1 agonists (87-89) motivated design of analogous insulin products.”
BackgroundMass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics
Anapindi, K. D. B., Romanova, E. V., Checco, J. W., & Sweedler, J. V. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000423 · Cited by 26
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15258 · Cited by 28
“11 Treatments with these drugs once a week have been associated with better adherence to therapy than regimens requiring once a day administration.”
BackgroundSeeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“More recently, an oral version of semaglutide has become available ( 119 ) ( 120 , 121 ).”
BackgroundThe GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
DeVries, J. H., Desouza, C., Bellary, S., Unger, J., Hansen, O. K. H., Zacho, J., & Woo, V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13396 · Cited by 24
“) administration.(10,11) SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a global phase III clinical trial programme, designed to evaluate the efficacy and safety of once-weekly s.”
BackgroundPratley, R. E., Catarig, A., Lingvay, I., Viljoen, A., Paine, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Miresashvili, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14497 · Cited by 26
“controlled on metformin alone, as well as those with established cardiovascular disease regardless of HbA1c.(2,3) However, semaglutide differs from dulaglutide in molecular structure and is smaller in size, which may lead to differences in metabolic effects.”
BackgroundInfluentialPharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“In the pancreas, GLP-1 receptors act in a glucose-dependent manner to stimulate insulin secretion and inhibit glucagon release [32,33].”
BackgroundInfluentialBellido, V., Padín, C. A., Catarig, A., Clark, A., Pittol, S. B., & Delgado, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174938 · Cited by 25
“It has a long half-life, which makes it suitable for once-weekly (OW) dosing, [13] and is the only GLP-1RA that is available both in a OW subcutaneous (s.”
BackgroundHach, M., Engelund, D. K., Mysling, S., Mogensen, J. E., Schelde, O., Haselmann, K. F., Lamberth, K., Vilhelmsen, T. K., Malmstrøm, J., Højlys-Larsen, K. B., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03771-6 · Cited by 23
“The A8Aib modification reduces enzymatic degradation by dipeptidyl peptidase 4 (DPP-4), which together with the fatty di-acid–mediated binding to albumin, gives semaglutide a prolonged half-life of approximately 7 days, allowing for once-weekly administration [20].”
How multispecific molecules are transforming pharmacotherapy
Deshaies, R. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01262-w · Cited by 29
Computational design and genetic incorporation of lipidation mimics in living cells
Ding, W., Liu, C., Chen, Y., Gu, J., Fang, C., Hu, L., Zhang, L., Yuan, Y., Feng, X., & Lin, S. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01400-8 · Cited by 23
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Li, X., Qie, S., Wang, X., Zheng, Y., Liu, Y., & Liu, G. (2018) · Endocrine · doi:10.1007/s12020-018-1708-z · Cited by 29
Half-Life Extending Modifications of Peptide YY3–36 Direct Receptor-Mediated Internalization
Bech, E. M., Kaiser, A., Bellmann‐Sickert, K., Bohr, S. S.-R., Sørensen, K. K., Elster, L., Hatzakis, N. S., Pedersen, S. L., Beck‐Sickinger, A. G., & Jensen, K. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00554 · Cited by 24
Bird, G. H., Patten, J. J., Zavadoski, W., Barucci, N., Godes, M., Moyer, B. M., Owen, C. D., DaSilva-Jardine, P., Neuberg, D. S., Bowen, R. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44361-1 · Cited by 22
“The further enhancement of albumin binding af fi nity and blockade of dipeptidyl peptidase IV (DPP-4) proteolysis by amino acid substitution combined to endow the lipopeptide semaglutide with a half-life of one week, making it viable for clinical use 36 .”
BackgroundMethodInfluentialWang, Y., Du, J., Zou, H., Liu, Y., Zhang, Y., Gonzalez, J., Chao, E., Lu, L., Yang, P., Parker, H., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201606321 · Cited by 23
Guryanov, I., Orlandin, A., de Paola, I., Viola, A., Biondi, B., Badocco, D., Formaggio, F., Ricci, A., & Cabri, W. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00021 · Cited by 22
Juul, A., Backeljauw, P. F., Højby, M., Kawai, M., Kildemoes, R. J., Linglart, A., Zuckerman‐Levin, N., & Horikawa, R. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac008 · Cited by 22
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
Park, E. J., Lim, S. M., Lee, K. C., & Na, D. H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1192130 · Cited by 22
“conjugated GLP-1 analog, semaglutide, which is currently in phase 3 clinical trials for T2DM [40].”
BackgroundPechenov, S., Bhattacharjee, H., Yin, D., Mittal, S., & Subramony, J. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.01.006 · Cited by 25
Bukrinski, J. T., Sønderby, P., Antunes, F., Andersen, B., Schmidt, E. G. W., Peters, G. H. J., & Harris, P. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00492 · Cited by 27
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 23
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Di Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
“Semaglutide has 94% sequence homology with native GLP-1 and three key structural differences that provide extended pharmacokinetics: substitution of Ala with Aib at position 8 increases enzymatic (DPP4) stability, attachment of a linker and C18 di-acid chain at position 26 provides strong binding to albumin, and subst…”
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide‑1 Receptor
Bird, G. H., Fu, A., Escudero, S., Godes, M., Opoku-Nsiah, K., Wales, T. E., Cameron, M. D., Engen, J. R., Danial, N. N., & Walensky, L. D. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00308 · Cited by 22
Han, W., Wang, L., Ohbayashi, K., Takeuchi, M., O’Farrell, L. S., Coşkun, T., Rakhat, Y., Yabe, D., Iwasaki, Y., Seino, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15001 · Cited by 22
From in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics
Pastorin, G., Benetti, C., & Wacker, M. G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114906 · Cited by 23
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems
Wu, B., Wang, J., Chen, Y., & Fu, Y. S. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01744 · Cited by 23
Lee, J.-H., Lim, H., Ma, G., Kweon, S., Park, S. J., Seo, M., Lee, J.-H., Yang, S.-B., Jeong, H., & Park, J. (2024) · Nature Communications · doi:10.1038/s41467-024-50819-7 · Cited by 21
“%) concentrations to determine whether they bind to albumin and whether their anticoagulant effects are maintained after binding 40 .”
Frich, C. K., Krüger, F., Walther, R., Domar, C., Andersen, A. H. F., Tvilum, A., Dagnæs‐Hansen, F., Denton, P. W., Tolstrup, M., Paludan, S. R., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.016 · Cited by 25
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Varanko, A. K., & Chilkoti, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801509 · Cited by 23
Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control
Tsao, C., Zhang, P., Yuan, Z., Dong, D., Wu, K., Niu, L., McMullen, P., Luozhong, S., Hung, H., Cheng, R. Y.-H., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00286 · Cited by 21
Lingvay, I., Bauer, R., Baker‐Knight, J., Lawson, J., & Pratley, R. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab905 · Cited by 22
“For commercial re-use, please contact journals.permissions@oup.com An indirect treatment comparison of semaglutide 2.0 mg versus dulaglutide 3.0 mg and 4.5 mg using multilevel network meta-regression Ildiko Lingvay,1 Robert Bauer,2 James Baker-Knight,2 Jack Lawson,2 Richard Pratley.3 1 Department of Internal Medicine/…”
BackgroundInfluentialInnovative chemical synthesis and conformational hints on the lipopeptide liraglutide
Guryanov, I., Bondesan, A., Visentini, D., Orlandin, A., Biondi, B., Toniolo, C., Formaggio, F., Ricci, A., Zanon, J., & Cabri, W. (2016) · Journal of Peptide Science · doi:10.1002/psc.2890 · Cited by 21
Rodbard, H. W., Bellary, S., HRAMIAK, I. M., Seino, Y., Silver, R., Damgaard, L. H., Nayak, G., Zacho, J., & Aroda, V. R. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0444 · Cited by 20
The latest trends in peptide drug discovery and future challenges
Otvos, L. J. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2365969 · Cited by 21
“For example, the long fatty-acid side chain on Semaglutide improves the half-life in the blood by binding to serum albumin [7].”
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20
“27,28 Dulaglutide and albiglutide are modified GLP-1 molecules attached to larger proteins — an immunoglobulin Fc fragment 29 and albumin, 30 respectively — further enhancing their duration of action.”
Cui, J., Shang, A., Wang, W., & Chen, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118339 · Cited by 20
Comparison of Protocols to Test Peptide Stability in Blood Plasma and Cell Culture Supernatants
Kohler, A., Jülke, E., Stichel, J., & Beck‐Sickinger, A. G. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00503 · Cited by 20
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Therapeutic peptides and proteins: Status and developments in drug delivery
Hornsby, B. D., Lee, C. H., Steele, C. A., Tuekpe, J. K. K., & Lim, C. S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114895 · Cited by 25
Poupon-Bejuit, L., Hughes, M. P., Liu, W., Geard, A. F., Faour-Slika, N., Whaler, S. M., Massaro, G., & Rahim, A. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-17338-1 · Cited by 20
Sun, H., Xi, M., Jin, Q., Zhu, Z., Zhang, Y., Jia, G., Zhu, G., Sun, M., Zhang, H., Ren, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00937 · Cited by 22
Zhou, K. Q., Dhillon, S. K., Bennet, L., Gunn, A. J., & Davidson, J. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710191 · Cited by 20
“Semaglutide is a modified version of Liraglutide that has a longer half-life allowing for the potential of single dosing rather than multiple doses or a continuous infusion [95].”
BackgroundSpurzem, G. J., Broderick, R. C., Ruiz-Cota, P., Hollandsworth, H. M., Sandler, B. J., Horgan, S., Grunvald, E. L., & Jacobsen, G. R. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11308-6 · Cited by 20
Mikulášková, B., Holubová, M., Pražienková, V., Zemenová, J., Hrubá, L., Haluzík, M., Železná, B., Kuneš, J., & Maletínská, L. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-017-0015-8 · Cited by 20
Jendle, J., Birkenfeld, A. L., Polonsky, W. H., Silver, R., Uusinarkaus, K., Hansen, T., Håkan‐Bloch, J., Tadayon, S., & Davies, M. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13816 · Cited by 19
“4 | DISCUSSION Efficacy and safety data from clinical trials are key factors for clinicians when considering treatment options for patients with T2D.”
BackgroundInfluential
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.